ErSO

ErSO is an experimental anticancer drug which induces the unfolded protein response. In tests on mice it was effective at eliminating xenografts of human breast cancer cell lines. While it is at an early developmental stage and this particular molecule may not be developed for medical use, it represents an important proof of concept for inducers of unfolded protein response as a novel class of anti-cancer drugs.^{[1][2][3][4][5]}

ErSO

Identifiers
IUPAC name (3R)-3-(4-hydroxyphenyl)-3-[4-(trifluoromethoxy)phenyl]-7-(trifluoromethyl)-1H-indol-2-one
CAS Number	2407860-35-7
PubChem CID	149494442
ChEMBL	ChEMBL5266426
Chemical and physical data
Formula	C22H13F6NO3
Molar mass	453.340 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC2=C(C(=C1)C(F)(F)F)NC(=O)[C@]2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)OC(F)(F)F
InChI InChI=1S/C22H13F6NO3/c23-21(24,25)17-3-1-2-16-18(17)29-19(31)20(16,12-4-8-14(30)9-5-12)13-6-10-15(11-7-13)32-22(26,27)28/h1-11,30H,(H,29,31)/t20-/m1/s1 Key:ZFSRXAHDJSCEDS-HXUWFJFHSA-N